Free tool
Cell therapy stocks
We cover 27 companies grouped under the Cell therapy theme. The median market value in the group is $437.45M. Across the group, the median move over the past trading day is −1.80%. 67% of the 27 with a 200-day average trade above it. Price change over the past year runs from −34.2% to +131.0% across the middle 80 percent of the group, with a median of +17.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
27 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $4.02B | Mid cap | −40.44% | Nov 11, 2026 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.66B | Mid cap | +233.88% | Nov 5, 2026 |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +4.47% | Aug 27, 2026 |
| VCEL | Vericel Corporation | $2.17B | Mid cap | +18.25% | Nov 5, 2026 |
| VOR | Vor Biopharma Inc. | $1.30B | Small cap | −40.82% | Nov 12, 2026 |
| SANA | Sana Biotechnology, Inc. | $1.25B | Small cap | +23.44% | Nov 5, 2026 |
| CYRX | Cryoport, Inc. | $839.26M | Small cap | +88.94% | Nov 3, 2026 |
| ALLO | Allogene Therapeutics, Inc. | $704.80M | Small cap | +75.86% | Nov 5, 2026 |
| PROK | ProKidney Corp. | $694.58M | Small cap | −30.12% | Nov 9, 2026 |
| AUTL | Autolus Therapeutics plc | $620.16M | Small cap | +48.41% | Nov 16, 2026 |
| KYTX | Kyverna Therapeutics, Inc. | $546.70M | Small cap | +133.33% | Nov 11, 2026 |
| CABA | Cabaletta Bio, Inc. | $545.94M | Small cap | +116.67% | Nov 16, 2026 |
| CAPR | Capricor Therapeutics, Inc. | $481.97M | Small cap | +49.76% | Nov 10, 2026 |
| IPSC | Century Therapeutics, Inc. | $392.93M | Small cap | +315.53% | Nov 12, 2026 |
| LYEL | Lyell Immunopharma, Inc. | $362.68M | Small cap | +37.32% | Nov 6, 2026 |
| CLLS | Cellectis S.A. | $344.40M | Small cap | +28.09% | Nov 13, 2026 |
| RNAC | Cartesian Therapeutics, Inc. | $308.30M | Small cap | −4.09% | Nov 5, 2026 |
| FATE | Fate Therapeutics, Inc. Common Stock | $305.54M | Small cap | +129.46% | Nov 12, 2026 |
| LCTX | Lineage Cell Therapeutics, Inc. | $283.26M | Small cap | −8.20% | Nov 5, 2026 |
| NKTX | Nkarta, Inc. | $194.10M | Small cap | +17.41% | Nov 10, 2026 |
| MXCT | MaxCyte, Inc. | $139.33M | Small cap | −6.43% | Nov 11, 2026 |
| ATRA | Atara Biotherapeutics, Inc. | $94.15M | Micro cap | −24.05% | Nov 12, 2026 |
| ACET | Adicet Bio, Inc. | $83.79M | Micro cap | −26.01% | Nov 11, 2026 |
| INKT | MiNK Therapeutics, Inc. | $60.16M | Micro cap | −26.22% | Nov 12, 2026 |
| TVGN | Tevogen Inc. | $43.63M | Micro cap | −85.43% | Nov 13, 2026 |
| LGVN | Longeveron Inc. | $21.68M | Micro cap | −14.44% | Nov 4, 2026 |
| CRBU | Caribou Biosciences, Inc. | — | — | −16.67% | Nov 11, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.